RESUMO
Lasalocid sodium is a polyether carboxylic ionophore agent authorized by the EU for use as a coccidiostat in broilers, turkeys, and pullets up to 16 weeks of age, except for laying hens. However, laying hens are the most common nontarget species exposed to lasalocid sodium, mainly due to cross-contamination from feed mills. This exposure may result in potential drug residue deposition in eggs, which could potentially expose consumers to the drug. The breeds commonly used for commercial egg production in Poland are Isa Brown and Green-legged Partridge hens, which have been found to significantly differ in egg-laying performance. This variability may also affect the pharmacokinetics of lasalocid. Data on lasalocid plasma pharmacokinetics in laying hens are lacking. In this study, we aimed to determine typical population pharmacokinetic parameters, absolute oral bioavailability, and how breed may influence the pharmacokinetics of lasalocid. Twenty-layer hens of the two breeds were used in this study. Lasalocid was administered orally at a single dose of either 1 mg or 5 mg/kg body weight or intravenously at a dose of 1 mg/kg body weight, in a crossover design with a three-week washout period between study periods. Blood samples were collected for 72 h, and lasalocid concentrations were measured using high-performance liquid chromatography with fluorescence detection. A population pharmacokinetic analysis was conducted using nonlinear mixed effects modeling. Standard numerical and graphical criteria were used to select the best model, and a stepwise covariate modeling approach was used to determine any influencing factors. The best model was a three-compartment mammillary model with first-order absorption, transit compartments, and linear elimination. The estimated absolute oral bioavailability was low (36%). It was found that breed significantly influenced not only absorption but also the elimination of lasalocid. This study revealed that lasalocid absorption and elimination varied between the two breeds. This variability in pharmacokinetics may result in breed-related differences in drug residue accumulation in eggs, and ultimately, the risk associated with consumer exposure to drug residues may also vary.
Assuntos
Disponibilidade Biológica , Galinhas , Lasalocida , Animais , Galinhas/metabolismo , Feminino , Lasalocida/farmacocinética , Lasalocida/administração & dosagem , Lasalocida/metabolismo , Administração Oral , Coccidiostáticos/farmacocinética , Coccidiostáticos/administração & dosagem , Coccidiostáticos/sangue , Ovos/análise , PolôniaRESUMO
Poultry production is linked with the use of veterinary medicinal products to manage diseases. Ionophore coccidiostats have been permitted for use as feed additives within the European Union (EU) for the prevention of coccidiosis in various species of poultry with except of laying hens. The presence of chemical residues in eggs is a matter of major concern for consumers' health. Despite such prohibition of use in laying hens, they were identified as the most common non-target poultry species being frequently exposed to these class of coccidiostats. Many factors can influence the presence of residues in eggs. Carryover of these class of coccidiostat feed additives in the feed of laying hens has been identified as the main reason of their occurrence in commercial poultry eggs. The physicochemical properties of individual compounds, the physiology of the laying hen, and the biology of egg formation are believed to govern the residue transfer rate and its distribution between the egg white and yolk compartments. This paper reviews the causes of occurrence of residues of ionophore coccidiostats in eggs within the EU with special emphasis on their disposition kinetics in laying hens, and residue transfer into eggs. Additional effort was made to highlight future modeling perspectives on the potential application of pharmacokinetic modeling in predicting drug residue transfer and its concentration in eggs.
Assuntos
Coccidiostáticos , Animais , Feminino , Coccidiostáticos/farmacocinética , Galinhas , Gema de Ovo/química , Ionóforos , Ração Animal/análise , Óvulo , OvosRESUMO
Piglet coccidiosis due to Cystoisospora suis is a major cause of diarrhea and poor growth worldwide. It can effectively be controlled by application of toltrazuril (TZ), and oral formulations have been licensed for many years. Recently, the first parenteral formulation containing TZ in combination with iron (gleptoferron) was registered in the EU for the prevention of coccidiosis and iron deficiency anemia, conditions in suckling piglets requiring routine preventive measures. This study evaluated the absorption and distribution of TZ and its main metabolite, toltrazuril sulfone (TZ-SO2), in blood and intestinal tissues after single oral (20 mg/kg) or single intramuscular (45 mg/piglet) application of TZ. Fifty-six piglets were randomly allocated to the two treatment groups. Animals were sacrificed 1-, 5-, 13-, and 24-days post-treatment and TZ and TZ-SO2 levels were determined in blood, jejunal tissue, ileal tissue, and mixed jejunal and ileal content (IC) by high performance liquid chromatography (HPLC). Intramuscular application resulted in significantly higher and more sustained concentrations of both compounds in plasma, intestinal tissue, and IC. Higher concentrations after oral dosing were only observed one day after application of TZ in jejunum and IC. Toltrazuril was quickly metabolized to TZ-SO2 with maximum concentrations on day 13 for both applications. Remarkably, TZ and TZ-SO2 accumulated in the jejunum, the primary predilection site of C. suis, independently of the administration route, which is key to their antiparasitic effect.
Assuntos
Coccidiostáticos/metabolismo , Coccidiostáticos/farmacocinética , Mucosa Intestinal/metabolismo , Sulfonas/metabolismo , Sulfonas/farmacocinética , Triazinas/metabolismo , Triazinas/farmacocinética , Administração Oral , Animais , Peso Corporal/efeitos dos fármacos , Coccidiose/prevenção & controle , Coccidiose/veterinária , Coccidiostáticos/administração & dosagem , Íleo/metabolismo , Injeções Intramusculares , Jejuno/metabolismo , Sulfonas/administração & dosagem , Suínos , Doenças dos Suínos/prevenção & controle , Triazinas/administração & dosagemRESUMO
Ponazuril, a novel coccidiocidal triazinetrione, has shown promise in addressing apicomplexan diseases in mammals and birds. This study describes the pharmacokinetics of ponazuril in healthy adult Indian peafowl (Pavo cristatus) following a single oral dose administered at two different dosages. Peafowl (four males and four females) were administered compounded ponazuril at 20 or 40 mg/kg orally in a double crossover design, with a 2-wk washout period. Blood was collected from each bird at 2, 4, 8, 24, 48, 72, 96, and 120 h after administration for plasma concentration of ponazuril using high-pressure liquid chromatography. Fecals were evaluated for coccidial shedding for 3 consecutive d prior to the ponazuril trial, 1 wk after the first dose of ponazuril, and 1 wk after the second dose of the trial. After the first trial, one peafowl administered 20 mg/kg ponazuril was shedding coccidia, but no coccidia were detected by the end of the second trial. Ponazuril reached peak concentrations (Tmax) at 21.38 h + 5.25 and 22.04 h + 7.39, and peak concentration (Cmax) were 11.82 µg/ml + 3.01 and 18.42 µg/ml + 4.13, for 20 and 40 mg/kg doses, respectively. Ponazuril was detected at 120 h with a concentration of 9.48 µg/ml + 2.59 and 12.25 µg/ml + 2.89 and a half-life of 219.4 + 58.7 h and 186.7 + 58.7 h, for and 40 mg/kg doses, respectively. Ponazuril in peafowl was well absorbed orally, plasma concentrations increased with dose, and elimination was slower than current dosages for birds would suggest. No obvious adverse effects were observed at either dosage.
Assuntos
Coccidiostáticos/farmacocinética , Galliformes/metabolismo , Triazinas/farmacocinética , Administração Oral , Animais , Coccidiostáticos/sangue , Coccidiostáticos/química , Relação Dose-Resposta a Droga , Fezes/química , Feminino , Masculino , Triazinas/sangue , Triazinas/químicaRESUMO
The treatment effect of ethanamizuril (EZL) to broiler chickens experimentally infected with 8â¯×â¯104Eimeria tenella was evaluated. On the third day after infection, the broiler chickens were treated with EZL by gavage at doses of 2, 4, and 8â¯mg/kg body weight (bw) for once. For double administration, the challenged broiler chickens were administered EZL at doses of 1, 2, 4, and 8â¯mg/kg bw by gavage continually on the third day and fourth day and once a day. Throughout the experimental period, performance parameters including body weight gain, mortality, cecal lesion score, bloody diarrhoea and oocyst output were recorded. The anticoccidial efficacy was evaluated using the anticoccidial index (ACI). Meanwhile, the concentrations of EZL in chicken cecal contents were measured, and the data were analyzed with a non-compartmental model. The results indicated that EZL showed good anticoccidial activity at single dose of 4â¯mg/kgbw, with the corresponding ACI of 175.73. When the challenged chickens were treated with EZL under double administration, the EZL showed a medium level of anticoccidial activity at a dose of 2â¯mg/kg bw, with the corresponding ACI of 162.48. The maximum concentrations (Cmax) of EZL in content were 2.43⯱â¯1.16, 4.28⯱â¯1.56, and 8.57⯱â¯1.33â¯mg/kg after the chickens were administrated at doses of 2, 4, and 8â¯mg/kg bw, respectively. The respective areas under the curve were 36.93⯱â¯8.91, 96⯱â¯16.31, and 262.76⯱â¯51.52â¯mg/kg h. The respective half-lives (T1/2) were 10.82⯱â¯2.02, 10.53⯱â¯2.23, and 10.60⯱â¯1.50â¯h. The results show that when the concentrations of EZL in chicken cecal contents reached 4.28⯱â¯1.56â¯mg/kg, there is a significant therapeutic effect on chicken coccidiosis.
Assuntos
Galinhas , Coccidiose , Coccidiostáticos , Eimeria tenella , Doenças das Aves Domésticas , Triazinas , Animais , Área Sob a Curva , Galinhas/parasitologia , Coccidiose/tratamento farmacológico , Coccidiose/parasitologia , Coccidiose/veterinária , Coccidiostáticos/farmacocinética , Coccidiostáticos/uso terapêutico , Redução da Medicação , Conteúdo Gastrointestinal/química , Meia-Vida , Doenças das Aves Domésticas/tratamento farmacológico , Doenças das Aves Domésticas/parasitologia , Triazinas/administração & dosagem , Triazinas/farmacocinética , Triazinas/uso terapêuticoRESUMO
The objectives of this study were to determine the pharmacokinetics of toltrazuril and its metabolites in pregnant and nonpregnant ewes following a single oral dose and to determine the plasma concentrations of these compounds in milk, allantoic fluid, and newborn plasma. Eighteen healthy ewes were randomly divided into three groups (n = 6 each): pregnant ewes at 12-13 weeks of gestation (group A), nonpregnant ewes (group B), and pregnant ewes at 1-2 weeks before expected lambing date (group C). Ewes in all groups received a single oral dose of toltrazuril at 20 mg/kg body weight. In groups A and B, blood samples were collected at 1, 3, 5, 7, 9, 12, 15, 18 hr, every 6 hr to day 3, every 12 hr to day 7 and thereafter every 24 hr to day 14 post-toltrazuril administration. In group C, parturition was induced 24-36 hr after toltrazuril administration then milk, allantoic fluid, and newborn plasma samples were collected immediately after birth. Drug metabolites were assayed using ultra high-performance liquid chromatography-ultraviolet detection method (UHPLC-UV). The maximum concentration (Cmax ), area under the plasma concentration-time curve (AUC0-t) , AUC to 24 and 48 hr (AUC0-24 ), and (AUC0-48 ) were significantly higher in pregnant ewes. Longer apparent half-life (T1/2 ), significantly higher apparent volume of distribution (Vd/F) and total clearance (Cl/F) were observed in nonpregnant ewes. The time to maximum plasma concentration (Tmax ), mean residence time (MRT) and elimination rate constant (Kel ) were similar in both groups. The AUC0-24 and AUC0-48 were significantly higher in nonpregnant ewes. The AUC0-t was significantly higher in pregnant ones. The ratio of plasma toltrazuril concentrations in ewes and toltrazuril concentrations in newborn lambs' plasma, allantoic fluid, and milk were 68%, 2.3%, and 5.3%, respectively. Results of this study showed that toltrazuril is well absorbed after a single oral dose in ewes with widespread distribution in different body tissues.
Assuntos
Animais Recém-Nascidos/metabolismo , Coccidiostáticos/farmacocinética , Leite/química , Ovinos/metabolismo , Triazinas/farmacocinética , Administração Oral , Animais , Animais Recém-Nascidos/sangue , Área Sob a Curva , Coccidiostáticos/administração & dosagem , Coccidiostáticos/sangue , Feminino , Meia-Vida , Troca Materno-Fetal , Gravidez , Distribuição Aleatória , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Ovinos/sangue , Triazinas/administração & dosagem , Triazinas/sangueRESUMO
Ethanamizuril(N-{4-[4-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-2-methyl-phenoxy]-phenyl}-acetamide, EZL) is a new anticoccidiosis compound and belongs to the class of triazines. In this study, the metabolism, distribution, and excretion of EZL were evaluated in chickens after administration of EZL at a single dosage. According to the relevant drug biotransformation rules, the exact molecular mass detection, the fragmentation characteristics, and the retention times, a total of five metabolites were identified in vivo in chickens, including two phase I metabolites and three phase II conjugated metabolites. The major metabolic pathways of EZL in chickens were deacetylation, hydroxylation, and glucuronidation. Regarding 14C-tissue residues after administration, kidney was considered to be the target tissue, as 14C-tissue residues could be detected at 240 h postdose. DeacetylEZL (M3) was the main metabolite, accounting for 68.65% and 25.62% of 14C in kidney at 6 and 24 h, respectively. In heart, muscle, skin+fat, and lung tissues, EZL was the main radioactive substance accounting for 94.88%, 97.32%, 96.23%, and 91.3% of 14C, respectively. In the liver, EZL and M3 were 20.76% and 54.65% of 14C, respectively. In chicken tissues the ratio of M5 was too low to be quantitated and it was mainly detected in chicken fecal and bile samples. In chicken excreta, EZL, M3, and glucuronidation of EZL (M5) accounted for 7.02%, 12.33%, and 10.32% of the dose, respectively and were eliminated primarily. This study presents the first detection of EZL metabolites, which is helpful for further understanding of the metabolic mechanism and in vivo intermediate processes of EZL. The results of this study will be good bases for better understanding EZL's anticoccidiosis mechanism and will serve as a helpful reference for assessing the risks to animals and humans.
Assuntos
Coccidiostáticos/farmacocinética , Triazinas/farmacocinética , Animais , Biotransformação , Galinhas , Coccidiostáticos/administração & dosagem , Coccidiostáticos/metabolismo , Hidroxilação , Rim/química , Rim/metabolismo , Fígado/química , Fígado/metabolismo , Pulmão/química , Pulmão/metabolismo , Músculos/química , Músculos/metabolismo , Triazinas/administração & dosagem , Triazinas/metabolismoRESUMO
Ethanamizuril is a new triazine compound that has the potential to be a novel anticoccidial drug. Toxicological studies in experimental rats were performed to understand the safety profile of ethanamizuril for drug product development. In this study, a novel, selective and accurate ultra-performance liquid chromatography tandem mass spectrometry method has been developed for the determination of ethanamizuril concentrations in rat plasma. With 4-nitro-o-cresol as an internal standard, sample pretreatment involved a one-step extraction with acetonitrile of 100 µL plasma. The detection was carried out by electrospray ionization mass spectrometry in negative ion mode with selected ion recording. The standard curves were linear (r2 ≥ 0.999) over the concentration range of 0.1-100 µg/mL. The relative standard deviations of intra- and inter-day precisions were less than 8.4 and 8.87%, respectively. The mean extraction recovery of ethanamizuril from rat plasma was 97.68-102.57%. The method was fully validated and successfully applied to monitor plasma concentrations of ethanamizuril in a short-term toxicity study and two-generation reproduction toxicity study. The result of the study confirmed that the elimination of ethanamizuril in rats is slow.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Coccidiostáticos/sangue , Espectrometria de Massas em Tandem/métodos , Triazinas/sangue , Animais , Coccidiostáticos/química , Coccidiostáticos/farmacocinética , Feminino , Limite de Detecção , Modelos Lineares , Masculino , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray , Triazinas/química , Triazinas/farmacocinéticaRESUMO
The purpose of this study was to determine if a low dose of diclazuril (0.5mg/kg of 1.56% diclazuril pellets) given to six healthy adult horses every 3-4 days for a total of five administrations would achieve steady-state plasma concentrations known to be inhibitory to Sarcocystis neurona and Neospora caninum. Blood was collected via venipuncture immediately before (trough concentrations) and 10h after (peak concentrations) each diclazuril administration and analysed by high-pressure liquid chromatography. The mean population-derived peak concentration was 0.284µg/mL and the mean terminal half-life was 1.6 days, but with a large variation. Thus, low dose diclazuril pellets produce steady-state plasma drug concentrations known to inhibit S. neurona (0.001µg/mL) and N. caninum (0.1µg/mL).
Assuntos
Coccidiostáticos/farmacocinética , Cavalos/metabolismo , Nitrilas/farmacocinética , Triazinas/farmacocinética , Administração Oral , Animais , Coccidiostáticos/administração & dosagem , Coccidiostáticos/sangue , Esquema de Medicação , Feminino , Cavalos/sangue , Masculino , Nitrilas/administração & dosagem , Nitrilas/sangue , Triazinas/administração & dosagem , Triazinas/sangueRESUMO
Coccidial disease is significant in tortoises; Testudines intranuclear coccidiosis (TINC), caused by an unnamed coccidia, causes high mortality in diverse tortoise species. There is a lack of information on anticoccidial drugs in tortoises. The drug ponazuril has demonstrated efficacy in treating mammals infected with similar coccidial disease. Previous empirical use of ponazuril in TINC cases suggests that it may be an effective treatment. In this study, 20 mg/kg of ponazuril was orally administered to tortoises with the goal of achieving blood concentrations known to be effective for anticoccidial therapy in mammals. Ponazuril was measured in tortoise plasma, and noncompartmental analyses of pharmacokinetic parameters were attempted. Ponazuril in these tortoises did not achieve the desired concentrations known to be effective for anticoccidial treatment in mammals. Tortoises showed prolonged oral absorption, and despite sampling for 168 hr (1 wk), a terminal elimination rate constant and half-life were not able to be determined. Additional studies are needed to fully characterize ponazuril pharmacokinetics in red-footed tortoises. The optimal dose for treating TINC remains to be determined.
Assuntos
Coccidiostáticos/farmacocinética , Triazinas/farmacocinética , Tartarugas/metabolismo , Administração Oral , Animais , Área Sob a Curva , Coccidiostáticos/sangue , Feminino , Meia-Vida , Masculino , Projetos Piloto , Triazinas/sangue , Tartarugas/sangueRESUMO
Toltrazuril (Tol) is a broad-spectrum anticoccidiosis drug that is widely used in the prevention and treatment of coccidiosis infection in poultry and mammals. However, the drug has poor aqueous solubility (25⯰C, 0.41⯵g/mL), and its dose escalation for systemic administration remains challenging. We engineered a Tol mixed nanomicelle (TMNM) delivery system based on sodium deoxycholate-Brij C20 polyethylene ether-triton x100 (NaDC-Brij58-Tx100) as surfactants by film hydration method. The physical properties of TMNM were characterized, and the pharmacokinetic parameters of Tol and TMNM were compared. The average particle size, drug loading, saturated solubility, and critical micelle concentration (CMC) of the TMNM system were 12.28⯱â¯0.48â¯nm, 3.38⯱â¯0.12%, 3921.70⯱â¯0.01⯵g/mL (8170-fold compared with Tol), and 0.0172â¯mg/mL, respectively. Transmission electron microscopy (TEM), scanning electron microscopy (SEM) micrographs, differential scanning calorimetry (DSC) and X-ray diffraction (XRD) were performed, and the results showed TMNM formation. Furthermore, the TMNM had greater bioavailability (215%) than the Tol solution. The significant increase in the drug solubility and bioavailability of TMNM suggested the TMNM is a potential oral and parenteral delivery system for Tol and has wide application prospects in the clinical context.
Assuntos
Coccidiostáticos/farmacocinética , Ácido Desoxicólico/química , Sistemas de Liberação de Medicamentos/métodos , Octoxinol/química , Polietilenoglicóis/química , Triazinas/farmacocinética , Animais , Disponibilidade Biológica , Coccidiostáticos/sangue , Composição de Medicamentos/métodos , Micelas , Tamanho da Partícula , Polidocanol , Coelhos , Solubilidade , Triazinas/sangueRESUMO
Ethanamizuril is a new triazine compound that displays potent anticoccidial activity against chicken coccidiosis caused by Eimeria tenella. We studied the pharmacokinetics of ethanamizuril in rats and chickens after single oral doses of one, two and three times the minimum effective dose Ethanamizuril was readily absorbed at all three doses and the plasma concentration reached was maximal within 5h and progressively declined over time. The mean peak plasma concentrations (Cmax) and the area under the concentration-time curve (AUC) were both dose-dependent. These results provide pharmacokinetic profiles of ethanamizuril for future preclinical studies and clinical use.
Assuntos
Galinhas , Coccidiose/veterinária , Coccidiostáticos/farmacocinética , Eimeria tenella , Doenças das Aves Domésticas/tratamento farmacológico , Triazinas/farmacocinética , Animais , Coccidiose/tratamento farmacológico , Relação Dose-Resposta a Droga , RatosRESUMO
The depletion times of the anticoccidial nicarbazin administered individually and of nicarbazin and narasin administered in combination were evaluated by determining the presence and levels of 4,4'-dinitrocarbanilide (DNC), the marker residue for nicarbazin, and narasin residues in the muscle tissues of broiler chickens subjected to a pharmacological treatment. A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was used. The results showed the presence of all anticoccidial residues; however, the DNC levels were higher when the nicarbazin was administered individually than when it was used in association with narasin throughout the experimental period. After six days of withdrawal, the DNC level following nicarbazin administration alone was lower than the maximum residue level (MRL) of 200 µg kg-1. However, when the nicarbazin was co-administered with narasin, the concentrations of DNC were lower than the MRL after four days of withdrawal. These results may be justified because the dosage of nicarbazin, when administrated individually, is greater than when it is used in combination with narasin. The levels of narasin were lower than the MRL of 15 µg kg-1 throughout the evaluation period. It was concluded that nicarbazin is rapidly metabolized from the broiler muscles up to six days of withdrawal since the DNC levels were lower than the maximum residue level (MRL) and the concentrations of narasin were lower than the MRL throughout the evaluation period.
Assuntos
Coccidiostáticos/farmacocinética , Nicarbazina/farmacocinética , Piranos/farmacocinética , Administração Oral , Animais , Galinhas , Coccidiostáticos/administração & dosagem , Combinação de Medicamentos , Resíduos de Drogas , Inocuidade dos Alimentos , Nicarbazina/administração & dosagem , Piranos/administração & dosagemRESUMO
This study investigates the effects of micro-environment modification and polymer type on the in-vitro dissolution behavior and in-vivo performance of micro-environment pH modifying solid dispersions (pHM-SD) for the poorly water-soluble model drug Toltrazuril (TOL). Various pHM-SDs were prepared using Ca(OH)2 as a pH-modifier in hydrophilic polymers, including polyethylene glycol 6000 (PEG6000), polyvinylpyrrolidone k30 (PVPk30) and hydroxypropyl methylcellulose (HPMC). Based on the results of physicochemical characterizations and in-vitro dissolution testing, the representative ternary (Ca(OH)2:TOL:PEG6000/HPMC/PVPk30=1:8:24, w/w/w) and binary (TOL:PVPk30=1:3, w/w) solid dispersions were selected and optimized to perform in-vivo pharmacokinetic study. The micro-environment pH modification improved the in-vitro water-solubility and in-vivo bioavailability of parent drug TOL. Furthermore, the addition of alkalizers not only enhanced the release and absorption of prototype drug, but also promoted the generation of active metabolites, including toltrazuril sulfoxide (TOLSO) and toltrazuril sulfone (TOLSO2). The in-vitro dissolution profiles and in-vivo absorption, distribution and metabolism behaviors of the pHM-SDs varied with polymer type. Moreover, in-vivo bioavailability of three active pharmaceutical ingredients increased with an increase in in-vitro dissolution rates of the drug from the pHM-SDs prepared with various polymers. Therefore, a non-sink in-vitro dissolution method can be used to predict the in-vivo performance of pHM-SDs formulated with various polymers with trend consistency. In-vitro and in-vivo screening procedures revealed that the pHM-SD composed of Ca(OH)2, TOL and PVPk30 at a weight ratio of 1:8:24, of which the safety was adequately proved via histopathological examination, may be a promising candidate for providing better clinical outcomes.
Assuntos
Coccidiostáticos , Polímeros , Triazinas , Animais , Coccidiostáticos/administração & dosagem , Coccidiostáticos/química , Coccidiostáticos/farmacocinética , Liberação Controlada de Fármacos , Concentração de Íons de Hidrogênio , Polímeros/administração & dosagem , Polímeros/química , Polímeros/farmacocinética , Coelhos , Solubilidade , Triazinas/administração & dosagem , Triazinas/química , Triazinas/farmacocinéticaRESUMO
The presence of mycotoxins in broiler feed can have deleterious effects on the wellbeing of the animals and their performance. Mycotoxin binders are feed additives that aim to adsorb mycotoxins in the intestinal tract and thereby prevent the oral absorption of the mycotoxin. The simultaneous administration of coccidiostats and/or antimicrobials with mycotoxin binders might lead to a reduced oral bioavailability of these veterinary medicinal products. This paper describes the influence of 3 mycotoxin binders (i.e., clay 1 containing montmorillonite, mica, and feldspars; clay 2 containing montmorillonite and quartz; and yeast 1 being a modified glucomannan fraction of inactivated yeast cells) and activated carbon on the oral bioavailability and pharmacokinetic parameters of the antimicrobials doxycycline and tylosin, and the coccidiostats diclazuril and salinomycin. A feeding study with 40 15 day-old broilers was performed evaluating the effects of long-term feeding 2 g mycotoxin binder/kg of feed. The birds were randomly divided into 5 groups of 8 birds each, i.e., a control group receiving no binder and 4 test groups receiving either clay 1, clay 2, yeast 1, or activated carbon mixed in the feed. After 15 d of feeding, both the control and each test group were administered doxycycline, tylosin, diclazuril, and salinomycin, consecutively, respecting a wash-out period of 2 to 3 d between each administration. The 4 medicinal products were dosed using a single bolus administration directly in the crop. After each bolus administration, blood was collected for plasma analysis and calculation of the main pharmacokinetic parameters and relative oral bioavailability (F = area under the plasma concentration-time curve (AUC0-8 h) in the test groups/AUC0-8 h in the control group)*100). No effects were observed of any of the mycotoxin binders on the relative oral bioavailability of the coccidiostats (i.e., F between 82 and 101% and 79 and 93% for diclazuril and salinomycin, respectively). Also, no significant effects could be noticed of any of the mycotoxin binders on the relative oral bioavailability of the antimicrobials doxycycline and tylosin (i.e., F between 67 and 83% and between 43 and 104%, respectively).
Assuntos
Antibacterianos/farmacocinética , Galinhas/metabolismo , Coccidiostáticos/farmacocinética , Micotoxinas/antagonistas & inibidores , Administração Oral , Animais , Disponibilidade Biológica , Doxiciclina/farmacocinética , Nitrilas/farmacocinética , Piranos/farmacocinética , Distribuição Aleatória , Triazinas/farmacocinética , Tilosina/farmacocinéticaRESUMO
The abundance of Toxoplasma gondii with or without sulfamethoxazole (SMX) treatment was evaluated with quantitative competitive polymerase chain reaction in various organs of wild-type C57BL/6 mice, a susceptible immunocompetent host, after peroral infection with a cyst-forming Fukaya strain of T. gondii. SMX affected different organs in three ways: T. gondii was reduced independently of SMX (skin and kidney); T. gondii was not eradicated with continuous treatment (brain, heart, and lung); and T. gondii was eradicated with continuous treatment (tongue, skeletal muscle, and small intestine). The SMX concentrations in the brains, hearts, and lungs were higher in infected mice than in uninfected mice. These results indicate that even in an immunocompetent host, chemotherapy is necessary to reduce the parasite load and thus reduce the risk of recurrent disease.
Assuntos
Coccidiostáticos/uso terapêutico , Imunocompetência , Sulfametoxazol/uso terapêutico , Toxoplasma/efeitos dos fármacos , Toxoplasmose Animal/tratamento farmacológico , Toxoplasmose Animal/parasitologia , Animais , Encéfalo/metabolismo , Encéfalo/parasitologia , Coccidiostáticos/farmacocinética , Coccidiostáticos/farmacologia , DNA de Protozoário , Modelos Animais de Doenças , Coração/parasitologia , Pulmão/metabolismo , Pulmão/parasitologia , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Carga Parasitária , Reação em Cadeia da Polimerase em Tempo Real , Sulfametoxazol/farmacocinética , Sulfametoxazol/farmacologia , Toxoplasma/genética , Toxoplasma/crescimento & desenvolvimentoRESUMO
Decoquinate, a chemical coccidiostat used as a feed additive, can occur in eggs due to cross-contamination of feedstuffs for laying hens. An experiment was designed to assess the transfer of decoquinate to hen eggs and its distribution between egg yolk and egg white. Hens were given the feed containing decoquinate at a cross-contamination level (0.34 mg kg(-1)) and collected eggs were analysed using an LC-MS/MS method. The plateau level was reached on the eighth day of the experiment and averaged 8.91 µg kg(-1), which is far below the maximum level established at 20 µg kg(-1) for whole eggs. Decoquinate was deposited mostly in egg yolks (26.2 µg kg(-1)) and did not deplete completely during 14 days of administration of decoquinate-free feed. The results confirmed that administration of cross-contaminated feed is associated with very low risk of non-compliant residue levels of decoquinate in eggs.
Assuntos
Ração Animal/análise , Galinhas , Decoquinato/farmacocinética , Resíduos de Drogas/farmacocinética , Ovos/análise , Contaminação de Alimentos/análise , Animais , Coccidiostáticos/química , Coccidiostáticos/metabolismo , Coccidiostáticos/farmacocinética , Decoquinato/química , Decoquinato/metabolismo , Resíduos de Drogas/química , Resíduos de Drogas/metabolismo , FemininoRESUMO
RATIONALE: Nitromezuril is a novel triazine compound possessing remarkable anticoccidial activity that could have possible future use in the prevention of coccidiosis; however, its metabolic characteristics have still not been revealed. METHODS: In the present study, the in vitro metabolism of nitromezuril in HepG2 cells, rat S9 and primary hepatocytes was investigated using high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. The structures of metabolites and their product ions were easily and reliably characterized based on the accurate MS(2) spectra and known structure of nitromezuril. RESULTS: As expected, three metabolites (M1-M3) were detected in a HepG2 cells system, one metabolite was respectively detected and identified as M1 in rat S9 and M2 in rat primary hepatocytes. M1 and M2 were confirmed respectively based on comparing their retention times, full scan, product ion scan with available authentic standards and M3 was tentatively identified as hydroxyl compound of M2. CONCLUSIONS: Pathways of nitromezuril were reported for the first time and no obvious species difference was shown. The proposed metabolic pathways of nitromezuril can be expected to play a key role in pharmacodynamics and food safety evaluations.
Assuntos
Cromatografia Líquida/métodos , Coccidiostáticos/farmacocinética , Hepatócitos/metabolismo , Espectrometria de Massas em Tandem/métodos , Triazinas/farmacocinética , Animais , Células Cultivadas , Humanos , Ratos , Especificidade da EspécieRESUMO
Semduramicin is an ionophore coccidiostat used in the poultry industry as a feed additive. Cross-contamination of feeds for non-target animals with semduramicin is unavoidable. However, it is not known whether undesirable residues of semduramicin may occur in food after cross-contaminated feed is administered to animals. The aim of the work was to determine the levels of semduramicin in hen eggs (yolks and albumen) and tissues (liver, muscle, spleen, gizzard, ovarian yolks and ovaries) after administration of feed contaminated with 0.27 mg kg(-1) of this coccidiostat. The residues were determined using LC-MS/MS. The distribution pattern confirmed the high lipophilicity of semduramicin. Residues were found mainly in egg yolks (28.8 µg kg(-1)), ovarian yolks (19.5 µg kg(-1)) and liver (2.57 µg kg(-1)), while hens' muscle was free from semduramicin (LOD = 0.1 µg kg(-1)). Among edible tissues, the maximum level (2 µg kg(-1)) was exceeded only in the liver.
Assuntos
Coccidiostáticos/farmacocinética , Ovos/análise , Contaminação de Alimentos , Nigericina/análogos & derivados , Animais , Galinhas , Coccidiostáticos/análise , Resíduos de Drogas/análise , Resíduos de Drogas/farmacocinética , Feminino , Nigericina/análise , Nigericina/farmacocinética , Distribuição TecidualRESUMO
A study on pharmacokinetics of ponazuril in piglets was conducted after a single oral dose of 5.0 mg/kg b.w. Plasma concentrations were measured by high-performance liquid chromatography assay with UV detector at 255-nm wavelength. Pharmacokinetic parameters were derived by use of a standard noncompartmental pharmacokinetic analysis. Samples from six piglets showed good plasma concentrations of ponazuril, which peaked at 5.83 ± 0.94 µg/mL. Mean ± SD area under the plasma concentration-time curve was 1383.42 ± 363.26 h/µg/mL, and the elimination half-life was 135.28 ± 19.03 h. Plasma concentration of ponazuril peaked at 42 h (range, 36-48 h) after administration and gradually decreased but remained detectable for up to 33 days. No adverse effects were observed during the study period. The results indicate that ponazuril was relatively well absorbed following a single dose, which makes ponazuril likely to be effective in swine.